DOCSLIB.ORG

| Oral Chemotherapy Monitoring & Counseling

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
| Oral Chemotherapy Monitoring & Counseling | Oral Chemotherapy Monitoring & Counseling Medication Dose/FDA Indication Monitoring Parameters Key Counseling Points Afinitor® (everolimus) HR+, HER2- breast cancer BBW: None Administration: Swallow tablet whole, don’t crush or chew (with exemestane); pNET; • Take consistently with regards to food 2.5, 5, 7.5, 10mg Blister pack: RCC: 10mg PO daily Baseline & periodically: CBC w/ differentials, SCr, fasting serum • Avoid grapefruit/juice 28 tablets glucose/lipids • Missed dose should be taken if <6 hrs (4 x 7 tabs each) Disperz 2, 3, 5mg SEGA: Initial 4.5mg/m2, • Liver dysfxn: dose adj. based on Child Pugh score • Hazardous agent, use precautions when handling Blister pack: tablets for titrate at week 2 to attain • Dose adj. based on ADE (see PI) oral suspension trough conc. of 5-15ng/mL • S/sx of infection or new or worsening respiratory symptoms ADE: Stomatitis, N/V/D, cough, dyspnea, peripheral edema, rash, (4 x 7 tabs each) fatigue, decreased appetite, HTN DDI: CYP3A4 substrate (major) MOA: mTOR inhibitor • dose to 2.5mg daily with CYP3A4 inhibitor • risk of angioedema with ACE-inhibitor Alecensa® (alectinib) Anaplastic lymphoma BBW: None Administration: kinase (ALK)-positive, • Take with food 150mg metastatic non-small cell Baseline & periodically: LFT, heart rate, BP, CPK • Do not open or dissolve the contents of the capsule Bottle: 240 capsules lung cancer (NSCLC) who * Embryo-fetal toxicity, use contraception during tx & 1 week after • If a dose is missed or vomiting occurs after taking a dose, take the final dose MOA: TKI of ALK & RET have progressed on or are next dose at the scheduled time intolerant to crizotinib: DDI: No pharmacokinetic interactions with alectinib requiring • Store in the original container to protect from light & moisture 600mg PO BID dosage adjustment have been identified ADE: Fatigue, constipation, edema, myalgia, rash, cough, N/V/D, dyspnea, anemia Alkeran® (melphalan) Ovarian, MM: Various BBW: Antineoplastic experienced doctor Administration: regimens exist • Store refrigerated 2mg Baseline & periodically: CBC with differentials • Take on empty stomach, food bioavailability Bottle: 50 tablets Typical: 0.2mg/kg to 10mg • Bone marrow suppression: Infection, bleeding or anemia • Perform good oral hygiene PO daily for up to 7 days MOA: Alkylating agent • Hazardous agent, use precautions when handling ADE: Bone marrow suppression, nausea, mouth sores, pulmonary toxicity Arimidex® (anastrozole)* Breast Ca: 1mg PO daily generic available 1mg tablet MOA: nonsteroidal inhibitor** BBW: None Aromasin® (exemestane) Breast Ca: 25mg PO daily Administration (Exemestane): Take after a meal generic available Baseline & periodically: (Anastrozole): LFTs & Bili q3-6 months ADE: Hot flashes, peripheral edema, N/V/D, arthralgia & weakness 25mg tablet ( frequency with hepatic metastases) • Thrombosis & hot flashes less common than with Tamoxifen DDI: w/ Tamoxifen effectiveness • Does not affect cortisol or aldosterone MOA: nonsteroidal inhibitor** • Not indicated for premenopausal women or women w/ ER- tumors • Long-term effects: Osteoporosis & hypercholesterolemia Femara® (letrozole) Breast Ca: 2.5mg PO daily generic available 2.5mg tablet MOA: nonsteroidal inhibitor** * Anastrozole is a nonsteroidal inhibitor that interferes with estradiol production in peripheral tissues by inhibiting conversion of adrenally-generated androstenedione to estrone by aromatase. ** Arimidex, Aromasin & Femara are Aromatase Inhibitors (available as daily dose) MARCH 2018 | 1 Medication Dose/FDA Indication Monitoring Parameters Key Counseling Points Bosulif® (bositinib) Chronic, accelerated or BBW: None Administration: Swallow tablets whole, don’t crush or chew blast phase Ph+CML 100mg • Take with food resistant or intolerant to Baseline & periodically: CBC with differential & platelets, SCr, LFT • Avoid grapefruit/juice Bottle: 120 tablets prior therapy: 500mg PO • dose to 200mg daily (If LFTs rise >5x ULN, hold until <2.5x ULN & • Missed dose should be taken if <12 hrs resume at 400mg) 500mg once daily (if no CHR by • Hazardous agent, use precautions when handling week 8 or CCyR by week 12 • CrCl 30-50ml/min: 400mg, <30ml/min:300mg Bottle: 30 tablets dose to 600mg daily) • Grade 3+ diarrhea or myelosuppression, hold until ≤Grade 1 & dose by ADE: Myelosuppression, N/V/D, abdominal pain, edema, fatigue, 100mg MOA: TKI of BCR-ABL headache, rash DDI: CYP3A4 substrate (major) Cabometyx™ Indicated for the BBW: Administration: 60mg orally once daily, do not eat for at least 2 hours (cabozantinib) treatment of patients None before and at least 1 hour after taking Cabometyx. Do not ingest foods 60mg Bottle: 30 tablets with advanced renal or nutritional supplements known to inhibit cytochrome P450 during cell carcinoma (RCC): Baseline & periodically: Clinical and radiologic evidence of tumor response may Cabometyx therapy. Swallow whole with a full glass of water; do not 40mg Bottle: 30 tablets Recommended dose is 60mg indicate efficacy, blood pressure, before drug initiation and regularly during therapy, crush tablet. 20mg Bottle: 30 tablets Signs and symptoms of perforations or fistulas once daily, patients instructed ADE: Hypertension, hair color changes, hypocalcemia, not to eat for at least 2 hours Concomitant use of Cabometyx with a strong CYP3A4 inhibitor increased the MOA: Inhibits the tyrosine DDI: hypophosphatemia, weight decreased, abdominal pain, constipation, before and at least 1 hour kinase activity of MET, exposure of Cabometyx compared to the use of Cabometyx alone decreased appetite, dental pain, diarrhea, nausea, stomatitis, after taking VEGFR-1, -2 and -3, AXL, • Increased Cabometyx exposure may increase the risk of exposure-related toxicity. taste sense altered, vomiting, lymphocytopenia, neutropenia, RET, ROS1, TYRO3, MER, Reduce the dosage of Cabometyx if concomitant use with strong CYP3A4 inhibitors thrombocytopenia, fatigue, elevated ALT/AST KIT, TRKB, FLT-3, and TIE-2. cannot be avoided (refer to PI for dosing recommendations) These receptor tyrosine Concomitant use of Cabometyx with a strong CYP3A4 inducer decreased the kinases are involved in both exposure of Cabometyx compared to the use of Cabometyx alone normal cellular function and • Decreased Cabometyx exposure may lead to reduced efficacy. Increase the pathologic processes such dosage of Cabometyx if concomitant use with strong CYP3A4 inducers cannot as oncogenesis, metastasis, be avoided (refer to PI for dosing recommendations) tumor angiogenesis, drug resistance, and maintenance of the tumor microenvironment. Calquence® (acalabrutinib) Adult patients with BBW: None Administration: 100mg orally approximately every 12 hrs; 100mg mantle cell lymphoma Baseline & periodically: CBC with differential & platelets, monitor for atrial swallow whole with water & with or without food Bottle: 60 capsules (MCL) who have received fibrillation & atrial flutter, S/S of infection ADE: Myelosuppression, headache, N/V/D, abdominal pain, at least one prior constipation, vomiting, fatigue, bruising, myalgia MOA: Inhibit Bruton DDI: therapy: Recommended tyrosine kinase (BTK) dose is 100mg orally • CYP3A inhibitor & inducer by covalently bonding approximately every twelve • Strong CYP3A inhibitor= avoid concomitant use. Interrupt Calquence therapy to a cysteine residue at hrs; swallow whole with if acute use, e.g. anti-infectives the active BTK site. This water & with or without • Moderate CYP3A inhibitor= 100mg once daily prevents activation of the food • Strong CYP3A INDUCER= avoid concomitant use. If inducers cannot be signaling proteins CD86 & avoided, increase Calquence dose to 200mg twice daily CD69, as well as inhibits • PPI’s= avoid concomitant use proliferation & survival of • H2-receptor antagonists= take Calquence 2 hrs before taking an malignant B cells H2-receptor antagonist • Antacids= separate dosing by at least 2 hrs MARCH 2018 | 2 Medication Dose/FDA Indication Monitoring Parameters Key Counseling Points Caprelsa® (vandetanib) Medullary thyroid cancer, BBW: None Administration: Don’t crush tablets, can be dispersed in 2oz of metastatic or locally water & swallow immediately 100, 300mg Baseline & periodically: CBC, serum electrolytes, TSH, BP, ECG advanced: 300mg PO daily • May take with or without food Bottle: 30 tablets • Dose adj. based on Grade 3+ ADE (see PI) • Avoid grapefruit/juice MOA: DDI: CYP3A4 substrate (major) • Missed dose should be taken if <12 hrs TKI of EGFR • QT prolongation additive effect ADE: HTN, fatigue, rash, N/V/D *Casodex® (bicalutamide) Metastatic prostate BBW: None Administration: May take with or without food generic available in combo with LHRH • Usually in combination with LHRH agonist analogs Baseline & periodically: LFTs (d/c if ALT >2x ULN or patient develops jaundice) 50mg agonist: 50mg PO daily • Hazardous agent, use precautions when handling • PSA Bottle: 30 tablets ADE: Hot flashes, gynecomastia, breast tenderness,decreased DDI: CYP3A4 inhibitor MOA: Androgen receptor libido, edema, arthralgia & weakness • Monitor INR closely with warfarin inhibitor *CeeNu® (lomustine) HL, malignant glioma: BBW: Antineoplastic experienced doctor Administration: Take on empty stomach as a single dose at generic available 100-130mg/m2 PO once bedtime, about 30 minutes after an antiemetic Baseline & periodically: CBC w/ differentials (dose adjust for platelets<75,000) q6wks • Hazardous agent, use precautions when handling 10, 40, 100mg • CrCl 10-50ml/min= by 25% dose Bottle: 20 capsules ADE: Myelosuppression (dose-limiting & delayed),
Load more

Recommended publications
  • A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax In
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open HOVON 141 CLL Version 4, 20 DEC 2018 A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥ 30 ml/min who have relapsed or refractory chronic lymphocytic leukemia (RR-CLL) with or without TP53 aberrations HOVON 141 CLL / VIsion Trial of the HOVON and Nordic CLL study groups PROTOCOL Principal Investigator : Arnon P Kater (HOVON) Carsten U Niemann (Nordic CLL study Group)) Sponsor : HOVON EudraCT number : 2016-002599-29 ; Page 1 of 107 Levin M-D, et al. BMJ Open 2020; 10:e039168. doi: 10.1136/bmjopen-2020-039168 BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open Levin M-D, et al. BMJ Open 2020; 10:e039168. doi: 10.1136/bmjopen-2020-039168 BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open HOVON 141 CLL Version 4, 20 DEC 2018 LOCAL INVESTIGATOR SIGNATURE PAGE Local site name: Signature of Local Investigator Date Printed Name of Local Investigator By my signature, I agree to personally supervise the conduct of this study in my affiliation and to ensure its conduct in compliance with the protocol, informed consent, IRB/EC procedures, the Declaration of Helsinki, ICH Good Clinical Practices guideline, the EU directive Good Clinical Practice (2001-20-EG), and local regulations governing the conduct of clinical studies.
    [Show full text]
  • Study Protocol
    Clovis Oncology, Inc. Clinical Protocol Oral rucaparib (CO-338) CO-338-014 7 July 2016 CONFIDENTIAL A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients with Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Protocol Number: CO-338-014 Investigational Product: Rucaparib (CO-338) Eudra CT Number: IND Number: Development Phase: Phase 3 Indications Studied: Platinum-sensitive, high-grade serous and endometrioid epithelial ovarian, primary peritoneal, and fallopian tube cancer Sponsor Name and Address: Clovis Oncology, Inc. 5500 Flatiron Parkway Suite 100 Boulder, CO 80301 USA Phone Number: 303-625-5000 Facsimile Number: 303-245-0360 Responsible Medical Officer: Compliance Statement: This study will be conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki, clinical research guidelines established by the Code of Federal Regulations (Title 21, CFR Parts 50, 56, and 312), and ICH GCP Guidelines. Essential study documents will be archived in accordance with applicable regulations. CONFIDENTIALITY STATEMENT The information in this document contains commercial information and trade secrets that are privileged or confidential and may not be disclosed unless such disclosure is required by applicable laws and regulations. In any event, persons to whom the information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed by them. These restrictions on disclosure will apply equally to all future information supplied to you which is indicated as privileged or confidential. 1 Clovis Oncology, Inc. Clinical Protocol Oral rucaparib (CO-338) CO-338-014 Coordinating Investigators for the Study Coordinating Investigator for North America: Coordinating Investigator for Europe, Middle East, and Asia Pacific: 2 Clovis Oncology, Inc.
    [Show full text]
  • Multi-Discipline Review/Summary, Clinical, Non-Clinical
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 209115Orig1s000 MULTI-DISCIPLINE REVIEW Summary / Clinical / Non-Clinical NDA/BLA Multi-disciplinary Review and Evaluation NDA 209115 Rubraca (rucaparib) 1 NDA/BLA Multi-disciplinary Review and Evaluation Application Type NDA Application Number(s) 209115 Priority or Standard Priority Submit Date(s) June 23, 2016 Received Date(s) June 23, 2016 PDUFA Goal Date February 23, 2017 Division/Office DOP1/OHOP Review Completion Date November 22, 2016 Established Name Rucaparib (Proposed) Trade Name RUBRACA Pharmacologic Class Poly (ADP-Ribose) Polymerase 1 inhibitor Code name AG-014669, PF-01367338, Applicant Clovis Oncology, Inc. Formulation(s) Oral tablet Dosing Regimen 600 mg PO BID Applicant Proposed Rubraca is indicated as monotherapy treatment of advanced ovarian Indication(s)/Population(s) cancer in patients with deleterious BRCA-mutated tumors, inclusive of both germline BRCA and somatic BRCA mutations (as detected by an FDA approved test), and who have been treated with two or more chemotherapies. Recommendation on Accelerated approval Regulatory Action Recommended Rubraca™ is indicated as monotherapy for the treatment of patients Indication(s)/Population(s) with deleterious BRCA mutation (germline and/or somatic) associated (if applicable) advanced ovarian cancer who have been treated with two or more chemotherapies. Select patients for therapy based on an FDA-approved companion diagnostic for Rubraca. 1-1 Version date: February 1, 2016 for initial rollout (NME/original BLA reviews) Reference ID: 40178304028244 NDA/BLA Multi-disciplinary Review and Evaluation NDA 209115 Rubraca (rucaparib) Contents 1 NDA/BLA Multi-disciplinary Review and Evaluation .......................................................................... 1-1 Reviewers of Multi-Disciplinary Review and Evaluation ...........................................................................
    [Show full text]
  • PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide
    Published OnlineFirst October 5, 2015; DOI: 10.1158/1535-7163.MCT-15-0587 Cancer Biology and Signal Transduction Molecular Cancer Therapeutics PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway Florian Engert1, Cornelius Schneider1, Lilly Magdalena Weib1,2,3, Marie Probst1,and Simone Fulda1,2,3 Abstract Ewing sarcoma has recently been reported to be sensitive to that subsequent to DNA damage-imposed checkpoint activa- poly(ADP)-ribose polymerase (PARP) inhibitors. Searching for tion and G2 cell-cycle arrest, olaparib/TMZ cotreatment causes synergistic drug combinations, we tested several PARP inhibi- downregulation of the antiapoptotic protein MCL-1, followed by tors (talazoparib, niraparib, olaparib, veliparib) together with activation of the proapoptotic proteins BAX and BAK, mitochon- chemotherapeutics. Here, we report that PARP inhibitors syner- drial outer membrane permeabilization (MOMP), activation of gize with temozolomide (TMZ) or SN-38 to induce apoptosis caspases, and caspase-dependent cell death. Overexpression of a and also somewhat enhance the cytotoxicity of doxorubicin, nondegradable MCL-1 mutant or BCL-2, knockdown of NOXA or etoposide, or ifosfamide, whereas actinomycin D and vincris- BAX and BAK, or the caspase inhibitor N-benzyloxycarbonyl-Val- tine show little synergism. Furthermore, triple therapy of ola- Ala-Asp-fluoromethylketone (zVAD.fmk) all significantly reduce parib, TMZ, and SN-38 is significantly more effective compared olaparib/TMZ-mediated apoptosis. These findings emphasize with double or monotherapy. Mechanistic studies revealed that the role of PARP inhibitors for chemosensitization of Ewing the mitochondrial pathway of apoptosis plays a critical role in sarcoma with important implications for further (pre)clinical mediating the synergy of PARP inhibition and TMZ.
    [Show full text]
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • The New Therapeutic Strategies in Pediatric T-Cell Acute Lymphoblastic Leukemia
    International Journal of Molecular Sciences Review The New Therapeutic Strategies in Pediatric T-Cell Acute Lymphoblastic Leukemia Marta Weronika Lato 1 , Anna Przysucha 1, Sylwia Grosman 1, Joanna Zawitkowska 2 and Monika Lejman 3,* 1 Student Scientific Society, Laboratory of Genetic Diagnostics, Medical University of Lublin, 20-093 Lublin, Poland; [email protected] (M.W.L.); [email protected] (A.P.); [email protected] (S.G.) 2 Department of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, 20-093 Lublin, Poland; [email protected] 3 Laboratory of Genetic Diagnostics, Medical University of Lublin, 20-093 Lublin, Poland * Correspondence: [email protected] Abstract: Childhood acute lymphoblastic leukemia is a genetically heterogeneous cancer that ac- counts for 10–15% of T-cell acute lymphoblastic leukemia (T-ALL) cases. The T-ALL event-free survival rate (EFS) is 85%. The evaluation of structural and numerical chromosomal changes is important for a comprehensive biological characterization of T-ALL, but there are currently no ge- netic prognostic markers. Despite chemotherapy regimens, steroids, and allogeneic transplantation, relapse is the main problem in children with T-ALL. Due to the development of high-throughput molecular methods, the ability to define subgroups of T-ALL has significantly improved in the last few years. The profiling of the gene expression of T-ALL has led to the identification of T-ALL subgroups, and it is important in determining prognostic factors and choosing an appropriate treatment. Novel therapies targeting molecular aberrations offer promise in achieving better first remission with the Citation: Lato, M.W.; Przysucha, A.; hope of preventing relapse.
    [Show full text]
  • Withdrawal Assessment Report - Orphan Maintenance
    17 January 2019 EMA/22653/2019 Committee for Orphan Medicinal Products Withdrawal Assessment Report - Orphan Maintenance Rubraca (rucaparib) Treatment of ovarian cancer EU/3/12/1049 (EMA/OD/085/12) Sponsor: Clovis Oncology UK Limited Note Assessment report as adopted by the COMP with all information of a commercially confidential nature deleted. 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged Table of contents 1. Product and administrative information .................................................. 3 2. Grounds for the COMP opinion at the designation stage .......................... 5 3. Review of criteria for orphan designation at the time of type II variation .................................................................................................................... 5 Article 3(1)(a) of Regulation (EC) No 141/2000 .............................................................. 5 Article 3(1)(b) of Regulation (EC) No 141/2000 .............................................................. 6 4. COMP list of issues .................................................................................. 8 Withdrawal Assessment Report - Orphan Maintenance EMA/22653/2019 Page 2/8 1. Product and administrative information Product Active substance Rucaparib International Non-Proprietary
    [Show full text]
  • Cancer Drug Pharmacology Table
    CANCER DRUG PHARMACOLOGY TABLE Cytotoxic Chemotherapy Drugs are classified according to the BC Cancer Drug Manual Monographs, unless otherwise specified (see asterisks). Subclassifications are in brackets where applicable. Alkylating Agents have reactive groups (usually alkyl) that attach to Antimetabolites are structural analogues of naturally occurring molecules DNA or RNA, leading to interruption in synthesis of DNA, RNA, or required for DNA and RNA synthesis. When substituted for the natural body proteins. substances, they disrupt DNA and RNA synthesis. bendamustine (nitrogen mustard) azacitidine (pyrimidine analogue) busulfan (alkyl sulfonate) capecitabine (pyrimidine analogue) carboplatin (platinum) cladribine (adenosine analogue) carmustine (nitrosurea) cytarabine (pyrimidine analogue) chlorambucil (nitrogen mustard) fludarabine (purine analogue) cisplatin (platinum) fluorouracil (pyrimidine analogue) cyclophosphamide (nitrogen mustard) gemcitabine (pyrimidine analogue) dacarbazine (triazine) mercaptopurine (purine analogue) estramustine (nitrogen mustard with 17-beta-estradiol) methotrexate (folate analogue) hydroxyurea pralatrexate (folate analogue) ifosfamide (nitrogen mustard) pemetrexed (folate analogue) lomustine (nitrosurea) pentostatin (purine analogue) mechlorethamine (nitrogen mustard) raltitrexed (folate analogue) melphalan (nitrogen mustard) thioguanine (purine analogue) oxaliplatin (platinum) trifluridine-tipiracil (pyrimidine analogue/thymidine phosphorylase procarbazine (triazine) inhibitor)
    [Show full text]
  • ARIEL4: an International, Randomised Phase 3 Study Of
    ARIEL4: An International, Randomised Phase 3 Study of Rucaparib vs Chemotherapy in BRCA1- or BRCA2-Mutated, Abstract ESGO7-0665 Relapsed Ovarian Cancer (OC) Rebecca S. Kristeleit,1 Domenica Lorusso,2 Ana Oaknin,3 Tamar Safra,4 Elizabeth M. Swisher,5 Igor M. Bondarenko,6 Tomasz Huzarski,7 Jaroslav Klat,8 Vladimir Moiseyenko,9 Róbert Póka,10 Luciana S. Viola,11 Chris Tankersley,12 Lara Maloney,12 Sandra Goble,12 Caro Unger,12 Adam Dowson,12 Heidi Giordano,12 Amit M. Oza13 1University College London Cancer Institute, London, UK; 2MITO and Unità di Ginecologia Oncologica, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 3Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain; 4Sackler School of Medicine, Tel Aviv University and Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; 5University of Washington, Seattle, WA, USA; 6Dnipropetrovsk Medical Academy, City Multiple-Discipline Clinical Hospital, Dnipropetrovsk, Ukraine; 7Private Health Care Innovative Medicine, Grzepnica, Poland; 8University Hospital Ostrava, Ostrava, Czech Republic; 9NN. Petrov Research Institute of Oncology Cancer Center, St. Petersburg, Russian Federation; 10Debrecen University Clinical Center, Debrecen, Hungary; 11Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil; 12Clovis Oncology, Inc., Boulder, CO, USA; 13Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada INTRODUCTION • In high-grade OC, including fallopian tube and primary peritoneal cancer, ≈18% and ≈7% of
    [Show full text]
  • Draft Matrix Post Referral PDF 189 KB
    Appendix C NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Single Technology Appraisal Venetoclax with a hypomethylating agent or low dose cytarabine for untreated acute myeloid leukaemia unsuitable for intensive chemotherapy [ID1564] Provisional stakeholder list of consultees and commentators Consultees Commentators (no right to submit or appeal) Company General • AbbVie (venetoclax) • All Wales Therapeutics and Toxicology Centre Patient/carer groups • Allied Health Professionals Federation • African Caribbean Leukaemia Trust • British National Formulary • Anthony Nolan • Care Quality Commission • Black Health Agency • Department of Health, Social Services • Bloodwise and Public Safety for Northern Ireland • Cancer Black Care • Hospital Information Services – • Cancer Equality Jehovah’s Witnesses • Cancer52 • Healthcare Improvement Scotland • DKMS • Medicines and Healthcare products • HAWC Regulatory Agency • Helen Rollason Cancer Charity • National Association of Primary Care • Independent Cancer Patients Voice • National Pharmacy Association • Leukaemia Cancer Society • NHS Alliance • Leukaemia CARE • NHS Blood and Transplant • Lymphoma Action • NHS Confederation • Macmillan Cancer Support • Scottish Medicines Consortium • Maggie’s Centres • Welsh Health Specialised Services • Marie Curie Committee • Muslim Council of Britain • South Asian Health Foundation Possible comparator companies • Specialised Healthcare Alliance • Accord Healthcare Ltd (cytarabine) • Tenovus Cancer Care • Bristol-Meyers Squibb Pharmaceuticals Ltd
    [Show full text]
  • A Novel CDK9 Inhibitor Increases the Efficacy of Venetoclax (ABT-199) in Multiple Models of Hematologic Malignancies
    Leukemia (2020) 34:1646–1657 https://doi.org/10.1038/s41375-019-0652-0 ARTICLE Molecular targets for therapy A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies 1 1 2,3 4 1 5 6 Darren C. Phillips ● Sha Jin ● Gareth P. Gregory ● Qi Zhang ● John Xue ● Xiaoxian Zhao ● Jun Chen ● 1 1 1 1 1 1 Yunsong Tong ● Haichao Zhang ● Morey Smith ● Stephen K. Tahir ● Rick F. Clark ● Thomas D. Penning ● 2,7 3 5 1 4 2,7 Jennifer R. Devlin ● Jake Shortt ● Eric D. Hsi ● Daniel H. Albert ● Marina Konopleva ● Ricky W. Johnstone ● 8 1 Joel D. Leverson ● Andrew J. Souers Received: 27 November 2018 / Revised: 18 October 2019 / Accepted: 13 November 2019 / Published online: 11 December 2019 © The Author(s) 2019 Abstract MCL-1 is one of the most frequently amplified genes in cancer, facilitating tumor initiation and maintenance and enabling resistance to anti-tumorigenic agents including the BCL-2 selective inhibitor venetoclax. The expression of MCL-1 is maintained via P-TEFb-mediated transcription, where the kinase CDK9 is a critical component. Consequently, we developed a series of potent small-molecule inhibitors of CDK9, exemplified by the orally active A-1592668, with CDK selectivity profiles 1234567890();,: 1234567890();,: that are distinct from related molecules that have been extensively studied clinically. Short-term treatment with A-1592668 rapidly downregulates RNA pol-II (Ser 2) phosphorylation resulting in the loss of MCL-1 protein and apoptosis in MCL-1- dependent hematologic tumor cell lines. This cell death could be attenuated by either inhibiting caspases or overexpressing BCL-2 protein.
    [Show full text]
  • Management of Multiple Myeloma: the Changing Paradigm
    Management of Multiple Myeloma: The Changing Paradigm Relapsed/Refractory Disease Jeffrey A. Zonder, MD Karmanos Cancer Institute Objectives • Discuss use of standard myeloma therapies when used as therapy after relapse • Consider patient and disease factors which might impact therapy decisions. • Describe off-label options for patients who are not protocol candidates. Line ≠ Line ≠ Line ≠ … POLICE LINE – DO NOT CROSS POLICE LINE – DO NOT CROSS POLICE LINE – DO NOT CROSS POLICE LINE – DO NOT CROSS POLI LINE – DO NOT Define “Line” • A pre-defined course of therapy utilizing agents either simultaneously or sequentially – Len/Dex – Len/Dex ASCT – Vel/Dex ASCT Len/Dex – VDT-PACE ASCT TD ASCT VPT-PACE LD • Pts who have had the same # of “lines” of Rx may have had vastly different amounts of Rx What Is Relapsed/Refractory Disease? • Relapsed: recurrence after a response to therapy • Refractory: progression despite ongoing therapy What Do We Know About the Pt’s Myeloma? • What prior therapy has been used? • How well did it work? • Did the myeloma progress on active therapy? • High-risk cytogenetics/FISH/GEP? What Do We Know About the Patient? • Age • Other medical problems – Diabetes – Blood Clots • Lasting side effects from past therapies – Peripheral Neuropathy • Personal preferences and values Choosing Therapy for Relapsed/Refractory Myeloma Proteasome IMiDs Anthracyclines Alkylators Steroids HDACs Antibodies Inhibitors Thalidomide Bortezomib Doxil Melphalan Dex Panobinostat Elotuzumab Lenalidomide Carfilzomib Cytoxan Pred Vorinostat
    [Show full text]